Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$558.17 USD

558.17
199,667

+2.02 (0.36%)

Updated Aug 30, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN's (QGEN) recent expansion in test menu and strategic collaborations.

Neogen's (NEOG) Q3 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Robust segmental performance and contributions from the Soleris product line drive the top line for Neogen (NEOG) in third-quarter of fiscal 2022 results.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

by Zacks Equity Research

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.

Why Holding Humana (HUM) in Your Portfolio is a Prudent Move

by Zacks Equity Research

Banking on better membership and strategic initiatives, Humana (HUM) holds immense potential to reap benefits for investors.

    Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

    by Zacks Equity Research

    Investors are optimistic about Thermo Fisher (TMO) on its progress with COVID-19-related products and services.

    Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays

    by Zacks Equity Research

    According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

    QIAGEN (QGEN) QuantiFeron Hits New Sales Landmark in TB Testing

    by Zacks Equity Research

    According to QIAGEN (QGEN), QuantiFERON is different from other IGRA tests based on its efficient workflow.

    Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research

    by Zacks Equity Research

    Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.

    Here's Why You Should Invest in Patterson Companies (PDCO) Stock

    by Zacks Equity Research

    Patterson Companies (PDCO) continues to benefit from strength in the Animal Health business and dental business.

    McKesson (MCK) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    McKesson (MCK) closed the most recent trading day at $300.02, moving +0.03% from the previous trading session.

    Should Value Investors Consider McKesson (MCK) Stock Now?

    by Zacks Equity Research

    Let's see if McKesson (MCK) stock is a good choice for value-oriented investors right now from multiple angles.

    Here's Why You Should Retain Change Healthcare (CHNG) Stock

    by Zacks Equity Research

    Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.

    Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care

    by Zacks Equity Research

    Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.

    Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair

    by Zacks Equity Research

    Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.

    Henry Schein (HSIC) Stock Moves Up 16.9%: What's Driving It?

    by Zacks Equity Research

    Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

    Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe

    by Zacks Equity Research

    Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.

    Humana (HUM) Taps Debt Market With Senior Note Pricing

    by Zacks Equity Research

    Humana (HUM) exhibits monetary discretion by pricing senior secured notes to procure funds.

      Thermo Fisher's (TMO) New Buyouts Aid, Cost Pressure Ails

      by Zacks Equity Research

      Thermo Fisher's (TMO) high degree of response to the pandemic has enabled it to accelerate its growth strategy, strengthen customer relationships, and bump up investments.

      McKesson (MCK) Is Up 6.34% in One Week: What You Should Know

      by Zacks Equity Research

      Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Here's Why You Should Retain Edwards Lifesciences (EW) Now

      by Zacks Equity Research

      Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.

      Myriad Genetics (MYGN) Makes Progress in Precision Oncology

      by Zacks Equity Research

      Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

      Here's Why You Should Hold on to Cerner (CERN) Stock Now

      by Zacks Equity Research

      Cerner (CERN) continues to gain traction from its robust strategic deals. However, stiff competition remains a woe.

      Here's Why You Should Retain Abbott (ABT) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about Abbott (ABT) backed by its progress in the diabetes business.